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ABSTRACT 
This study evaluated the perception of stature, acceptance of therapy, and psychosocial 
functioning in relation to age at onset and time on treatment during 2 yr of GH therapy in 31 girls 
with Turner’s syndrome grouped by age (group A: 3.7–5.8 yr, n = 9; group B: 7.2–11.8 yr, n = 13; 
group C: 12.5–16.4 yr, n = 9). The growth response after 2 yr was significant in the 3 groups when 
calculated in terms of growth norms for untreated Turner girls (mean increase in height SD score: 
+1.2, +1.5, and +1.1, respectively). The effect was less marked in terms of growth norms for normal 
girls, particularly in group B (+0.5 SD score). Height was perceived as a problem by most patients, 
except in the youngest girls at the start of treatment (group A) and in the majority of the 
adolescents after 2 yr of GH therapy (group C), without evidence of relation to growth response 
during therapy. The GH injections were fairly well accepted by all patients, except those younger 
than 6 yr. In all patients, expected adult height was unrealistic and became more realistic with age, 
whereas no consistent changes were observed in relation to growth response to GH therapy. The 
Child Behavior Checklist revealed elevated mean scores at the behavioral subscales of attention 
problems (group A and B), social problems, withdrawal, and anxiety-depression (most obviously in 
group B). No significant changes were seen during GH therapy. In group C, an elevated mean social 
problem score at the Youth Self Report and a low mean social self-esteem score at the Self-Esteem 
Inventory were observed before therapy and showed a significant improvement during 2 yr of GH 
treatment. These results, however, might be biased due to an increase in social desirability during 
therapy. We conclude that the perception of height, acceptance of GH therapy, and psychosocial 
functioning in girls with Turner’s syndrome show important differences between age groups, with 
only slight changes observed during GH therapy.
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In patients with Turner’s syndrome, psychosocial difficulties, including low self-esteem and social 
immaturity, have been described without evidence of psychopathological symptoms (1–4). 
Hyperactivity, poor concentration, and learning difficulties have been reported (5–7). Some 
researchers found that being short may negatively affect psychosocial functioning and self-esteem, 
although the severity of psychosocial problems associated with short stature is variable (8–12). In 
Turner’s syndrome, short stature alone could not explain the multiple psychosocial problems 
according to McCauley et al. and Skuse et al. (4, 7). Rovet et al., however, reported a positive 
correlation between height and social competence in patients with Turner’s syndrome (3). 
GH therapy undoubtedly results in increased growth velocity in Turner patients (13). The impact of 
GH therapy on psychosocial functioning has been studied by few researchers. In 66 short children, 
aged 5–15 yr, a beneficial effect on attitudes to being short was found after 2 yr of GH treatment, 
particularly in younger children (14). In a mixed group of GH-treated short patients, including girls 
with Turner’s syndrome, a positive attitude toward height and a high level of satisfaction and 
compliance with GH therapy were observed regardless of height gain (15). In contrast, a positive 
correlation between height velocity and improvement in psychosocial functioning was found by 
Rovet et al. in patients with Turner’s syndrome after 2 yr of GH therapy (16). The discrepancy 
between those data as well as controversies concerning the ultimate auxological and psychosocial 
benefits from GH therapy (17) led us to investigate the perception of stature and GH therapy as well 
as psychosocial functioning in a group of 31 children and adolescents with Turner’s syndrome 
during 2 yr of treatment using human GH (hGH). As there are important age-related changes in 
cognitive and affective development, we hypothesized that the perception of short stature and GH 
therapy as well as psychosocial functioning could be different according to age. Therefore, the 
patients were divided into 3 age groups. 
Subjects and Methods 
PATIENTS AND AUXOLOGICAL EVALUATION 
Thirty-one children with Turner’s syndrome who started GH therapy at ages ranging between 3.7–
16.4 yr were included in the study. The exclusion criteria were chronological age below 3 yr, bone 
age above 13 yr, spontaneous pubertal development or previous GH or sex or anabolic steroid 
therapy, and associated thyroid disorders or diabetes. Written informed consent from the parents 
and oral consent from the patients were obtained. The patients were followed during 2 yr in the 
Pediatric Endocrine Units of five Belgian University hospitals. GH (Humatrope, Eli Lilly & Co., 
Indianapolis, IN) was given as a daily sc injection at a dose of 0.15 IU/kg. No patient received 
estrogen replacement therapy during the first year of GH therapy. During the second year, six 
patients (group C, see below) were treated using ethinyl estradiol (50 ng/kg∙day) based on a 
decision made individually by each pediatric endocrinologist together with each patient. Four 
patients started estrogen therapy after 12 months, one after 18 months, and one after 21 months 
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of study. At 24 months of study, all six showed stage B2 breast development according to Tanner 
(18). 
Height was measured every 3 months using a wall-mounted stadiometer. Weight was also 
measured. Target height was calculated as proposed by Tanner et al. by adding father’s height to 
mother’s height, subtracting 13 cm, and dividing the total by two (19). SD scores of height were 
calculated in terms of growth norms for normal girls (20) and Turner girls (21). In each patient, a 
dysmorphy score was calculated using the following 17 findings, which each accounted for 1 point: 
short neck, webbed neck, micrognathia, low posterior hairline, palpebral ptosis, strabismus, 
impaired vision, dysmorphic low set ears, hearing impairment, cubitus valgus, short metacarpals, 
pectus excavatum, shield thorax, increased body hair, more than 20 pigmented nevi, and nail 
dysplasia. X-Ray films of the left hand and wrist were obtained annually, and bone age was 
estimated according to the method of Tanner and Whitehouse, TW2 RUS, by a single experienced 
pediatric radiologist (22). The patients were divided into 3 groups according to chronological age 
at the onset of treatment (Table 1). Time between diagnosis and initiation of the study was variable 
and, on the average, shorter in the older patients. There were no significant differences among the 
3 age groups with respect to target height and dysmorphy score (Table 1) or pretreatment height 
SD score in terms of growth norms for Turner girls (Table 2). Although all but 1 patient in group A 
had the classical 45X karyotype, the majority of patients in groups B and C showed other 
karyotypes, listed in Table 1. 
Table 1. Clinical data of Turner patients before starting GH therapy. 
 Group A (3–6 yr) Group B (7–12 yr) Group C (13–16 yr) 
n 9 13 9 
Chronological age (yr) 4.8 ± 0.7 9.9 ± 1.4 14.2 ± 1.4 
Time since diagnosis (yr) 3.4 ± 1.9 2.5 ± 3.6 0.2 ± 0.1 
Target ht (cm) 165.8 ± 4.8 162.1 ± 5.9 162.4 ± 4.5 
Dysmorphy score 7.4 ± 3.1 8.4 ± 3.0 6.1 ± 2.0 
Karyotype    
      45X 8 4 4 
      45X/46XX 1 1  
      45X/46Xi(Xq)  3 2 
      46Xi(Xq)   1 
      45X/47XXX   1 
      45X/46XY/47XYY  1  
      45X/46XY   1 
      45X/46Xt(X)/47Xt(XX)  1  
      45X/46Xt(XY)  1  
      45X/46X, r(X)  2  
Data are the mean ± SD. 
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Two psychologists (K.L. and D.X.H.), one Dutch and one French-speaking, performed the study so 
as to have families interviewed in their mother tongue. The psychological evaluation took place 1 
month before initiating GH therapy and after 1 and 2 yr of therapy. 
Standardized questionnaires were used to evaluate behavior, intellectual skills, and global 
psychosocial functioning. The Child Behavior Checklist (CBC), developed by Achenbach et al. (23), 
was used as a standardized measure of social competence and behavioral problems in children 
aged 2–18 yr and was completed by the parents. The Youth Self Report (YSR), a checklist evaluating 
similar aspects as the CBC, was completed by patients older than 11 yr. In this study, the Dutch and 
French versions were used (23, 24). The CBC and the YSR consist of a total social competence scale 
(including activity, school, and social competence) and a behavior scale (including eight 
subscales). In this report, we emphasized the data from four behavioral subscales at which the 
mean scores appeared to be most relevant: attention problems (poorly concentrated, acting 
young, nervous, daydreaming, impulsive, clumsy), social problems (teased, preferring younger 
children, not getting along, overweight), withdrawal (shy, secretive, underactive), and 
anxiety/depression (lonely, sad, worthless, fearful, guilty). 
Table 2. Growth data of Turner patients before and after 1 and 2 yr of GH therapy. 
 Group A (3–6 yr; n = 9) Group B (7–12 yr; n = 13) Group C (13–16 yr; n = 9) 
Baseline Yr 1 Yr 2 Baseline Yr 1 Yr 2 Baseline Yr 1 Yr 2 
Ht SD score 
(in terms of growth 
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Data are the mean ± SD. 
a P ≤ 0.05 vs. baseline. 
For the CBC, individual raw scores were transformed into T scores (mean = 50, SD = 10) using the 
American norms (23). These T scores were transformed into SD scores. The behavioral problem 
scores were considered to be borderline when the SD score was more than 1.6 (T score, > 66; 95th 
percentile) and within the clinical range when the SD score was above 2 (T score, > 70; 98th 
percentile). The Self-Esteem Inventory (SEI), developed by Coopersmith, was completed by 
patients older than 8 yr (25). The total self-esteem comprises four subscales: social, general, 
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school, and family self-esteem. These subscales measure how the child evaluates, respectively, her 
social contacts, herself in general, herself at school, and herself within the family. The social 
desirability or “lie” subscale measures the degree of wanting to present herself as she thinks that 
she is socially best accepted. For the SEI, the individual scores were transformed into SD scores 
using the American norms (25). In school age children and young adolescents (groups B and C), the 
intellectual abilities were assessed by the Wechsler Intelligence Scale for Children-Revised (WISC-
R). The age- and sex-appropriate standards used were provided by the respective Dutch and 
French manuals (26, 27). 
Other screening instruments were used to evaluate the psychological functioning of the child: the 
observation of play, including the use of anatomical dolls; the Scenotest; and drawing. Semi-
structured interviews were developed to evaluate the perception of height and injections and to 
determine the specific behavioral and affective characteristics of each child with Turner’s 
syndrome. The interviews were designed according to the systemic theory and family therapy (28–
30). The evaluation involved interviews with the patient and her parents, as well as with the patient 
alone and with each of the seven pediatric endocrinologists taking care of the families. Upon 
written request, the semi-structured interviews will be forwarded to the reader. 
STATISTICAL ANALYSIS 
This descriptive, nonrandomized study consisted of an in-depth investigation of a limited number 
of patients. No control group was studied. Comparisons between the data obtained within each 
age group, before and after 1 and 2 yr of GH therapy, were made by ANOVA with correction for 
repeated measurements, followed by post-hoc Fisher’s protected least significant difference test. 
Comparisons of the SD score data between the age groups were performed by ANOVA followed by 
Scheffe’s F test for multiple comparisons. The correlation between various data was calculated by 




In the three age groups, the mean pretreatment height SD score (Table 2) and individual values (Fig. 
1) were within the normal range for Turner patients. When calculated in terms of growth norms for 
normal girls, the pretreatment height SD score was lower with age (Fig. 1). During the first and 
second years of GH treatment, mean height velocity and mean height SD score, calculated in terms 
of growth norms for normal as well as Turner girls, increased significantly in the three groups 
(Table 2). In group B, the increase in height SD score after 2 yr was more marked in terms of growth 
norms for Turner girls (+1.5) than in terms of growth norms for normal girls (+0.5). Some patients in 
group B showed a reduction in height SD score, particularly during the second year of treatment 
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(Fig. 1). During the 2 yr of therapy, the mean progression in bone age was greater in group A (+4.0 
yr) than in group B (+3.3 yr) and group C (+1.7 yr; Table 2). 
INTERVIEWS 
PERCEPTION OF HEIGHT AND INJECTIONS 
In patients younger than 6 yr, height was not perceived as a problem before starting GH therapy 
(Fig. 1). This was in contrast to all but 1 of the patients older than 6 yr. After 1 yr of treatment, 
height was still not perceived as a problem in 5 of the 7 patients younger than 6 yr at that time, 
including a patient with a height SD score of −2.8 vs. that in normal girls. In this group, perception of 
height as a problem was not consistent with actual stature, as some treated patients with height 
greater than −1 SD complained about height. After 2 yr of GH therapy, height remained a problem in 
the vast majority of patients older than 6 yr, particularly in group B (10 of 13 patients). In contrast, 
height remained a problem in only 3 of 9 patients in group C (Fig. 1). At the pretreatment interview, 
it appeared that the perspective of a treatment using daily injections was frightening for all 
patients in the 3 groups regardless of age. After 1 yr, the injections remained a problem in 4 of the 9 
patients in group A and in a minority of patients (3 of 22) in groups B and C. 
Fig. 1. Height changes during 2 yr of GH therapy in 31 girls with Turner’s syndrome divided into 3 age groups. 
The data were calculated in terms of growth norms for untreated Turner girls (upper panels) or normal girls 
(lower panels). For each individual patient, the data are connected by lines, and the symbols indicate 
whether height was perceived as a problem at each of the 3 evaluations. 
 
EXPECTATION ABOUT ADULT HEIGHT 
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The adult height anticipated by most patients was high in the three groups and appeared to 
decrease with age (Fig. 2). The older the patient, the more realistic was the expectation. However, 
most patients in group C still had overly optimistic expectations (adult height above −2 SD of 
normal women). No correlation was found between expected adult height and growth response to 
therapy. 
PSYCHOSOCIAL PROBLEMS 
In group A, hyperactivity, talkativeness, lack of concentration, impatience, and a tendency to 
dominate became obvious through observation during the interview sessions as well as through 
the complaints by the parents. These problems remained unchanged during the 2 yr of follow-up. 
In group B, the patients themselves expressed suffering from being teased about short stature. The 
parents were concerned about a tendency to withdraw. The interviews revealed that the patients 
invested more in schoolwork than their siblings, and they obtained less satisfactory results. The 
majority of patients did not participate in any social, cultural, or sports activity and were rather 
passive at home. In group C, the adolescents expressed feelings of inferiority at the start of the 
study. The complaints about a lack of self-confidence tended to decrease during the 2 yr of follow-
up. After 2 yr, a tendency to minimize problems became obvious. 
Fig. 2. Adult height expected by 31 girls with Turner’s syndrome divided into 3 age groups. The expected 
adult height was transformed into the SD score (in terms of growth norms for adult women). The data 




The mean intelligence quotient (IQ) was significantly lower (P < 0.05) in group B (mean ± SD, 91 ± 
15) than in group C (105 ± 14). Half of the patients (11 of 22) had average IQs ranging between 96–
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109. Two had IQs above average (113 and 116), and 2 were gifted (122 and 124). Six patients had 
borderline IQs ranging between 74–85, and 1 had mild mental retardation (68). 
STANDARDIZED QUESTIONNAIRES 
In group A, the mean attention problem score on the CBC was high at the 3 evaluations (Fig. 3). The 
individual attention problem scores were borderline or in the clinical range in a quarter of the 
patients at the start of treatment and in half of the patients after 2 yr. On the other subscales (Fig. 3 
and Table 3), the scores were within the normal range and remained so throughout the study. In 
group B, the mean attention problem score was elevated as well, with individual scores being 
borderline or in the clinical range in half of the patients before and after 2 yr of therapy. A high 
mean score on the social problem subscale was observed at the 3 evaluations, indicating social 
behavior inadequate for age. The individual social problem scores were borderline or clinical range 
in 3 of 13 patients at the start and in5 of13 after 2 yr of treatment. High mean behavior problem 
scores were also observed on the withdrawal and anxiety depression subscales (Fig. 3), and low 
mean social competence scores were observed on the activities, social, and school subscales 
(Table 3). No significant changes in mean score were seen throughout the study, except on the 
social competence subscale in group B. On the SEI (Fig. 4), the mean social self-esteem score was 
low in group B at the start of treatment and remained so throughout the study. In contrast, the 
mean family self-esteem score was high at the 3 evaluations. In group C, a high mean score was 
observed on the social problem subscale of the CBC, with a nonsignificant decrease during follow-
up (Fig. 3). On the other behavior problem subscales (Fig. 3 and Table 3), the scores were within the 
normal range and remained so throughout the study. On the activities and social subscales of the 
social competence scale, low mean scores were observed, with no change during the study (Table 
3). On the YSR, the mean social problem score was high at the start of treatment and decreased 
significantly after 2 yr of treatment (Table 4). High mean scores were also obtained on the anxiety-
depression subscale of the CBC (Fig. 3) and YSR (Table 4), and they showed some decrease during 
follow-up. Low mean scores of social competence were obtained on the YSR, and no changes were 
seen throughout the study (Table 4). It is noteworthy that the mean scores of the parents (CBC) 
were lower than those of the patients (YSR) on all subscales. On the SEI, the mean social and 
general self-esteem scores showed a significant increase throughout the study (Fig. 4). These score 
changes might be biased because the mean social desirability scores increased significantly 
throughout the study. A biasing effect of IQ was unlikely because the baseline SEI scores were not 
significantly correlated with the IQ scores. Neither were the baseline SEI scores correlated with the 
dysmorphy scores, indicating that variations in self-esteem were not simply determined by 
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Fig. 3. Mean (±SD) problem score (SD score) obtained on four behavioral subscales of the CBC in three age 
groups of Turner girls studied before and after 1 and 2 yr of GH therapy. 
 
Table 3. Behavior problem and social competence scores on the Child Behavior Checklist in three age groups 
(A, B, and C) of Turner patients at baseline and after 1 and 2 yr of GH therapy. 
Behavior problems Baseline Yr 1 Yr 2 
      Somatic complaints    
            Group A 0.36 ± 0.31 0.58 ± 0.52 0.40 ± 0.35 
            Group B 0.76 ± 0.82 0.69 ± 0.67 0.51 ± 0.57 
            Group C 0.28 ± 0.50 0.28 ± 0.46 0.40 ± 0.83 
      Thought problems    
            Group A 0.26 ± 0.54 0.20 ± 0.37 0.43 ± 0.56 
            Group B 0.46 ± 0.69 0.39 ± 0.52 0.55 ± 0.58 
            Group C 0.44 ± 0.57 0.25 ± 0.49 0.14 ± 0.43 
      Delinquent problems    
            Group A 0.36 ± 0.53 0.34 ± 0.60 0.48 ± 0.73 
            Group B 0.49 ± 0.66 0.42 ± 0.59 0.56 ± 0.68 
            Group C 0.34 ± 0.59 0.21 ± 0.42 0.14 ± 0.36 
      Aggressive behavior    
            Group A 0.42 ± 0.66 0.66 ± 0.89 0.64 ± 0.83 
            Group B 0.58 ± 0.65 0.60 ± 0.72 0.55 ± 0.78 
            Group C 0.21 ± 0.45 0.16 ± 0.46 0.07 ± 0.20 
      Externalizing    
            Group A −0.14 ± 1.17 0.08 ± 1.39 0.26 ± 1.20 
            Group B 0.35 ± 1.00 0.37 ± 0.98 0.26 ± 1.02 
            Group C −0.49 ± 1.01 −0.78 ± 1.00 −0.99 ± 0.82 
      Internalizing    
            Group A −0.01 ± 0.74 0.09 ± 0.84 −0.06 ± 0.80 
            Group B 0.73 ± 0.96 0.67 ± 0.74 0.68 ± 0.65 
            Group C −0.34 ± 1.12 −0.41 ± 0.89 −0.77 ± 1.33 
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      Total    
            Group A 0.16 ± 0.16 0.34 ± 0.97 0.21 ± 1.02 
            Group B 0.81 ± 0.93 0.68 ± 0.76 0.75 ± 0.68 
            Group C −0.31 ± 1.28 −0.44 ± 1.02 −0.89 ± 1.24 
Social competence    
      Activities    
            Group B −0.68 ± 0.70 −0.88 ± 0.54 −0.62 ± 0.61 
            Group C −1.09 ± 0.93 −1.19 ± 0.68 −1.19 ± 0.88 
      Social    
            Group B −0.64 ± 0.65 −0.87 ± 0.73 −1.36 ± 0.67a 
            Group C −1.03 ± 0.87 −0.84 ± 0.81 −1.14 ± 0.98 
      School    
            Group B −1.05 ± 0.74 −0.96 ± 0.99 −1.28 ± 0.89 
            Group C −0.17 ± 0.88 −0.65 ± 1.09 −0.60 ± 0.99 
      Total    
            Group B −0.97 ± 0.51 −1.24 ± 0.43 −1.45 ± 0.52 
            Group C −1.13 ± 0.91 −1.25 ± 0.74 −1.57 ± 0.94 
Scores are expressed as SD scores (mean ± SD). 
a P ≤ 0.05 vs. baseline. 
 
No significant correlation was found between the height gain during therapy and the individual 
differences in attention problem score, social problem score, and social selfesteem score. This was 
found analyzing the data from each of the three groups separately as well as analyzing the entire 
set of data together. 
Fig. 4. Mean (±SD) self-esteem score (SD score) obtained on four subscales of the SEI in two age groups of 
Turner girls studied before and after 1 and 2 yr of GH therapy. 
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Table 4. Behavior problem and social competence scores on the Youth Self Report in nine adolescent Turner 
patients (group C) at baseline and after 1 and 2 yr of GH therapy. 
 Baseline Yr 1 Yr 2 
Behavior problems    
      Attention problems 0.69 ± 0.89 0.41 ± 0.60 0.32 ± 0.42 
      Social problems 1.11 ± 0.80 1.07 ± 0.79 0.41 ± 0.57a 
      Withdrawal 0.44 ± 0.58 0.30 ± 0.46 0.13 ± 0.29 
      Anxiety/depression 0.74 ± 0.82 0.38 ± 0.49 0.22 ± 0.40 
      Somatic complaints 0.39 ± 0.51 0.12 ± 0.19 0.14 ± 0.34 
      Thought problems 0.28 ± 0.37 0.21 ± 0.43 0.12 ± 0.22 
      Delinquent behavior 0.44 ± 0.43 0.13 ± 0.40 0.13 ± 0.40 
      Aggressive behavior 0.25 ± 0.65 0.26 ± 0.49 0.14 ± 0.30 
      Externalizing −0.19 ± 1.08 −0.39 ± 0.80 −0.42 ± 0.72 
      Internalizing 0.06 ± 1.44 −0.24 ± 0.92 −0.49 ± .094 
      Total 0.06 ± 1.35 −0.27 ± 0.77 −0.50 ± 0.90 
Social competence    
      Activities −1.15 ± 1.10 −0.97 ± 1.31 −1.00 ± 0.78 
      Social −1.44 ± 0.87 −1.24 ± 0.85 −1.29 ± 0.89 
      Total −1.63 ± 0.73 −1.47 ± 0.83 −1.43 ± 0.84 
Scores are expressed as SD scores (mean ± SD). 
a P ≤ 0.05 vs. baseline. 
Discussion 
In this study, the perception of short stature and GH therapy by Turner patients as well as their 
psychosocial functioning appeared to be different according to age, with only slight changes 
during 2 yr of GH therapy. Neurocognitive functioning and behavioral problems in Turner patients 
can be influenced by many other factors besides age. Among these factors, brain structure 
anomalies (31), karyotype subgroups (3, 32), parental origin of the remaining X chromosome (33), 
and estrogen deficiency (34) may play some role. In this study, we cannot exclude either the 
confounding effect of brain structure anomalies, which was not investigated, or the potential 
estrogen effects because estrogen therapy was initiated after 1 yr of study in six patients from the 
adolescent group. Although the majority of non-45 XO karyotypes were found in groups B and C, 
there were only two patients with ring X chromosome, which is associated with high risk of mental 
retardation (32). However, due to the small number of patients in each age group and because 
there are no control untreated patients, the possible role of those factors cannot be delineated. 
Therefore, the age-related aspects described in this study deserve confirmation in larger groups of 
patients, taking into account the effects of genetic, neurological, and endocrine factors as well. 
Before the age of 6 yr, the patients did not yet perceive height as a problem, and they accepted the 
injections with difficulty. In GH-treated patients, Leiberman (15) noted that satisfaction and 
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compliance were high regardless of age at the start of treatment. We did not find such a 
satisfaction in Turner patients younger than 6 yr. At this early stage, the child does not yet have a 
realistic representation of height, and the rationale of treatment cannot be understood. According 
to the theory of Piaget (35) regarding cognitive development, the age period from 3–6 yr is 
characterized by magic and egocentric thinking; the child mixes reality and imagination. The young 
child with Turner’s syndrome may hold firmly to the idea “I am tall, even the tallest of the whole 
class,” even if she is objectively very short. In addition, affective development is characterized by 
investment in adults, particularly the parents, and comparison with peers is not yet so important. 
All children tend to idealize future perspectives without taking into account the real possibilities 
and limitations. Children younger than 6 yr in particular have difficulties projecting themselves into 
the future. This might explain the totally unrealistic expectations for adult height in these young 
patients. Turner girls younger than 6 yr showed several behavioral problems, such as hyperactive 
and impulsive behavior, poor concentration, talkativeness, and a need to dominate. Some of these 
features were confirmed by high attention problem scores on the CBC, which remained unchanged 
after 2 yr. Hyperactivity in young Turner girls was also described by Swillen et al. (5). Future studies 
in a larger number of young Turner patients might contribute to clarification of the etiology of the 
behavioral problems. In these young patients, it would also be interesting to study hypotheses 
such as the delayed neurological maturation hypothesis described by McCauley et al. in older 
patients (9–17 yr) (7). After 2 yr of GH therapy, the patients who were older than 6 yr perceived 
height in a more realistic way and compared themselves with peers. Height, however, was 
perceived as a problem by only five of nine patients, and social problems did not appear on the 
CBC, contrary to what could be expected at that age. These findings might be explained by the 
growth effects of GH therapy, which diminished the gap with peers. A long term follow-up of 
patients treated at a young age could further clarify whether perception of stature and GH therapy 
as well as psychosocial functioning in these young patients differ from those in patients starting 
GH therapy at an older age. 
Turner patients, aged 7–12 yr, subjectively suffered from short stature. They had attained an age at 
which comparison with peers became important. They took into account and suffered from 
remarks by others. At this stage, the patients were aware of their dysmorphic appearance and 
began to realize the consequences of Turner’s syndrome for pubertal development and fertility. 
Once they were 6 yr old, the patients showed high motivation, compliance, and satisfaction with 
GH therapy, as reported by others (36). This treatment created hope and required a great 
investment. This reinforced idealization and unrealistic expectations. According to Huisman et al. 
(36), the optimistic expectations for adult height in the patients were already striking before 
treatment and remained unchanged after 2 yr of therapy, in agreement with our findings. Although 
adult height expectations remained unrealistic, there was a decrease in some patients during 
therapy. This might be due to an age effect. There might also have been a biasing effect due to the 
psychologists having shared their concern about the unrealistic expectations of the patients with 
the pediatric endocrinologist. On the CBC, high scores on the attention problem, social problem, 
and anxiety/depression subscales were also found by Skuse et al. in a large group of girls with 
Turner’s syndrome (4). A high rate of hyperactivity was reported by McCauley et al. in 97 untreated 
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girls with Turner’s syndrome (1). Noteworthy, these studies were not set up in a longitudinal 
perspective. In our study, attention problems revealing distractibility, clumsiness, and poor school 
performance remained unchanged after 2 yr. In addition, as mean IQ was low in this group (6 of 13 
had an IQ < 90), it was not surprising that school results remained moderate despite a great 
investment. We did not evaluate the effect of GH treatment on neurocognitive function. In a recent 
study comparing Turner patients treated with GH or a placebo, no evidence was found of an 
influence of GH on childhood brain development (37). On the CBC, social problems, indicating 
social immaturity, were still obvious after 2 yr. Apparently, the catch-up in growth did not lead to a 
catch-up in psychosocial functioning. Even after 2 yr of GH therapy, the patients continued to be 
perceived as younger. It is noteworthy that despite growth acceleration during GH treatment, the 
height gap compared to normal girls was not reduced in these patients, as their normal peers were 
growing rapidly on account of pubertal development. Most patients did not complain openly about 
being lonely and isolated, but they tended to withdraw before as well as during therapy. Their 
social self-esteem was rather low, in contrast to their family investment, which increased. They 
tended to avoid confrontation with peers and took refuge in the family. After 2 yr, the majority of 
patients reported that peer derision about short stature diminished, and they had learned to react 
better to remarks from peers. They also reported that GH treatment helped them in creating hope 
of catching up with peers. They felt supported by doing something for their short stature, the only 
symptom that they could influence at that moment. This positive effect of GH treatment, however, 
did not resolve the ongoing suffering in children between 7–12 yr of age. 
In all Turner girls aged 13–16 yr, short stature was a problem at the start of GH therapy, and 
treatment was perceived as the last chance to influence height. Although a considerable height 
difference from that of their peers remained after 2 yr, only one third of these adolescents still 
perceived height as a problem. As they knew that final height was almost attained, they tried to 
accept this inevitable reality. These findings were consistent with a study in untreated adult Turner 
patients, who expressed greater distress due to infertility compared with short stature (38). At the 
start of GH therapy, lack of self-confidence and low self-esteem were obvious in the majority of 
patients. In this study, the low self-esteem could be partly understood by the particular age period 
of adolescence during which all youngsters are searching for their own identity, and much 
importance is accorded to physical appearance. Comparisons with peers are particularly hard for 
Turner adolescents due to the obvious physical differences from peers: short stature, dysmorphic 
appearance, and absence of female development, which, together with infertility, do affect the 
sense of being a woman. We have assessed the severity of dysmorphic features in the three groups, 
because Turner stigmata might have been less visible in late diagnosed patients. Such an 
explanation was unlikely, as the mean dysmorphy score was slightly, but not significantly, lower in 
group C than in group B. 
McCauley et al. (1) observed a decline in self-esteem in girls with Turner’s syndrome as they moved 
into the adolescent period. These patients, however, were younger (mean age, 10.2 yr) than the 
adolescent group studied in the present work. According to the patients in this study, the 
perspective of estrogen replacement therapy created the hope of contributing to the patient’s 
femininity just as GH therapy did for short stature. Ross et al. showed that estrogen therapy 
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resulted in improved self-concept and social behavior in Turner girls between 12–16 yr of age (34). 
This raised the question of whether the changes in self-esteem and behavior seen in adolescent 
Turner patients in this study could be related to estrogen therapy. Although this possibility was not 
excluded, only half of the adolescent patients were treated using estrogen, and such a treatment 
was only started after the first year of GH therapy. During this first year of study, however, a 
significant increase in self-esteem was already observed, indicating that some improvement might 
occur independently of estrogen therapy. 
After 2 yr of GH therapy, there was some improvement in psychosocial functioning of the 
adolescent patients. They were less anxious-depressed and had a better self-image and greater 
social self-esteem. They considered themselves less socially immature. These data are consistent 
with the findings of Huisman et al. (36). On the SEI, social desirability scores increased 
considerably. The patients tended to minimize their problems as a way of coping with them. The 
adolescent patients wanted to present themselves as doing better. Their family investment was 
high. They felt secure and tended to take refuge in the family to avoid the often painful 
confrontation with peers. The very close relationship with their parents, particularly with their 
mother, and the feeling of guilt because of causing many problems to the parents could push the 
patients toward a minimization of their problems. This could also be a reason why they could not 
revolt against their parents as do other adolescents. Again, the observed changes might have been 
influenced by the treatment with GH. As we did not study a group of untreated patients for control 
purposes, the interpretation of these findings requires prudence. Nevertheless, it is interesting that 
no correlation was found between the changes in psychosocial functioning and the growth 
response to therapy in the three age groups. 
In conclusion, this study shows that in Turner patients, perception of short stature, GH therapy, 
and expectation for adult height are different according to age. The psychological profile as well as 
the suffering caused by Turner’s syndrome vary according to the cognitive and affective 
development and change only slightly during 2 yr of GH therapy. These data might provide a 
rationale for an age-based evaluation of indications for GH therapy and benefits from such a 
treatment in girls with Turner’s syndrome. Treatment strategy should also take into account the 
possible adult height consequences of the rapid progression in bone maturation seen in young 
treated patients. This observation may indeed add to the questions about benefits from early 
onset of GH therapy. 
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